From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bearcast: I have sold all my Open Orphan shares now and explain why

By Tom Winnifrith | Tuesday 26 May 2020


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


First of all i hope you listen to the first of my now weekly long premium video podcasts which went out late last night HERE. It was a lot of work recording as I explain in this bearcast. It also gives background on my thinking on Covid-19 and that brings me to Novacyt (NCYT) which has company specific issues which will blow it up as I explain in yesterday's show and Open Orphan (ORPH) which is very well run and a great company but where I have sold my last shares. I explain why. I also look at Asiamet (ARS), Bluebird Merchant Ventures (BMV), 4D Pharma (DDDD) and Big Dish (DISH). Finally if you have yet to donate to Rogue Bloggers for Woodlarks , the great day looms and we are now at 31% so please donate HERE 

You must be a paid subscriber to listen to Bearcast
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 09:29:53